Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 3rd Annual Conference on Gynecologic Oncology & Preventive Oncology Chicago, Illinois, USA.

Submit your Abstract
or e-mail to

[email protected]
[email protected]
[email protected]

Day 1 :

Keynote Forum

Aaron H Chevinsky

University of Wisconsin Madison School of Medicine and Public Health, USA

Keynote: HIPEC for peritoneal malignancies
Gynec & Preventive Oncology 2017 International Conference Keynote Speaker Aaron H Chevinsky photo
Biography:

Aaron H Chevinsky is the Director of Surgical Oncology at Aurora Health Care in Wisconsin. He has lectured nationally and internationally and has published on many aspects of cancer care. He attended medical school and completed his surgical residency in New York, and completed a surgical oncology fellowship at Ohio State. He has been named to the Top Docs list and has won awards for the development of multidisciplinary cancer care programs. He also appeared on TV and radio to raise awareness and promote cancer screening he remains committed to providing the best cancer care to the patients he treats

Abstract:

The use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) for the treatment of peritoneal based malignancies has been ongoing in the Unites States and around the globe for well over 20 years. This procedure, which combines debulking of all visible cancer, often with peritonectomy, bowel resection, splenectomy and removal of other intra-abdominal organs with the infusion of chemotherapy heated to 42 degrees centigrade has been very effective in treating several malignancies which tend to involve the peritoneal surfaces, but has not metastasized or invaded deeply into other organs. The most commonly treated malignancies include pseudomyxoma peritonei, appendiceal, gastric, colorectal cancer, ovarian and primary peritoneal cancer, as well as peritoneal mesothelioma and recurrent sarcomas. It is estimated that as many as 50,000 patients a year in the United States may be candidates for a HIPEC procedure. The majority of the cases have used mitomycin C as the chemotherapy of choice, others have used platinum (oxaliplatin, cisplatin and carboplatin) based agents. Most patients with carcinomatosis will die within one year of diagnosis if untreated, and with HIPEC (depending on the initial tumor site) may have as much as a 60-70% five-year survival. In most patients their ascites (which is present in over half the patients) will be controlled and their quality of life will be improved. Studies are ongoing to evaluate the effectiveness of HIPEC in high risk cancers, prone to carcinomatosis, in the adjuvant setting after resection. In gynecologic malignancies, HIPEC has been primarily used in recurrent ovarian cancer, where it has been shown to improve survival and reduce recurrence. Post-operative complications include ileus, respiratory compromise, fluid retention and complications related to chemotherapy absorption (such as pancytopenia). A new HIPEC program was started at Aurora St. Luke’s Medical Center in Milwaukee, Wisconsin in September of 2016. To date we have attempted HIPEC on 10 patients, and have been successful in 9 (in one patient the disease was too extensive for effective debulking). The diagnoses included appendiceal cancer, primary peritoneal cancer, granulosa cell ovarian cancer and colorectal cancer. Our protocol for the evaluation of these complex patients, highlighted the need for multidisciplinary management, the integration of intravenous and intraperitoneal chemotherapy, and the intra-operative and post-operative management will be discussed in detail along with suggestions on how to initiate a HIPEC program at the institution.

Keynote Forum

Colleen Huber

Naturopathic Oncologist (FNORI), USA

Keynote: Optimal Diets for Cancer Patients
Gynec & Preventive Oncology 2017 International Conference Keynote Speaker Colleen Huber photo
Biography:

Dr. Colleen Huber is a Naturopathic Medical Doctor in Tempe, Arizona. Her clinic, Nature Works Best Cancer Clinic, has had the most successful results of any clinic in the world reporting its results over the last 9 years. President of the Naturopathic Cancer Society, whose primary aim is to inform the public of safe and effective natural treatments for: Breast Cancer, Colorectal Cancer, Gastric and Esophageal Cancer, Leukemias and Lymphomas, Liver and Biliary Tract Cancers, Lung Cancer, Ovarian and Uterine Cancers, Pancreatic Cancer, Prostate Cancer, Skin Cancer, General and Other Cancer

Abstract:

Background

Previous research has shown a correlation between blood sugar or glycemic load and cancer growth for a number of types of cancer.   This study is the largest of its kind to date: a 7-year interventional study of 317 human patients at one clinic, who were treated naturopathically, with nutrients and herbs, plus the recommended dietary intervention of abstention from sweetened foods.

Methods

We analyzed the clinical significance (mortality) of sweetened food consumption among all cancer patients at our clinic.  Since 2006, this clinic has collected data on sugar consumption in cancer patients, and has actively recommended, but never enforced, avoiding the consumption of sweetened foods (except with the sweetener Stevia Rebaudiana, which has no sugar content or sugar alcohol content).  In this controlled interventional study, we followed the diets and outcomes of all 317 cancer patients who came to our clinic with a diagnosis of cancer, and who stayed at least two weeks in our care.  We also look at consumption of other common foods and cancer outcome.

Results

The remission rate is significantly different for the following two categories:  all patients: 151 / 317 = 48% and those who ate sweetened foods: 9 / 29 = 31%.  However, the difference is much more pronounced if we consider those patients who continued our treatments until either remission or death.  Of all patients who were steadfast in the treatments (including our sweetened food eaters), 32 / 183 =  17% died while still under our care, but considering only the sweetened food eaters who were otherwise steadfast in the treatments, 16 / 25 = 64% died.

Conclusion

Consuming sweetened foods (other than stevia sweetened foods) made a significant difference in patient outcome across all stages and all types of cancer.

Gynec & Preventive Oncology 2017 International Conference Keynote Speaker Yoshiaki Omura photo
Biography:

Yoshiaki Omura received Oncological Residency training at Cancer Institute of Columbia University & Doctor of Science Degree through research on Pharmaco-Electro-Physiology of Single Cardiac Cells in-vivo and in-vitro from Columbia University. He researched EMF Resonance phenomenon between 2 identical molecules for non-invasive detection of molecules, at Graduate Experimental Physics Dept., Columbia University, for which he received U.S. patent. He is also the creator of Bi-Digital O-Ring Test. He published over 270 original research articles, many chapters, & 9 books. He is currently Adjunct Prof. of Family & Community Medicine, New York Medical College; President & Prof. of Int’l College of Acupuncture & Electro-Therapeutics, NY; Editor in Chief, Acupuncture & Electro-Therapeutics Research, Int’l Journal of Integrative Medicine, (indexed by 17 major int’l Indexing Periodicals); Formerly, he was also Adjunct Prof. or Visiting Prof. in Universities in USA, France, Italy, Ukraine, Japan, Korea, & China. 

Abstract:

Any cancer can be non-invasively, quickly, & safely detected using following methods: 1) Visible & invisible changes of accurate organ representation areas at specific part of the face including eyebrows, lips, nose, as well as tongue & hands. 2) One page of “Mouth, Hand, & Foot Writing Form”. 3) New method of detection of various cancers from rapidly changing QRS Complex as well as rising part of T-wave of ECGs. These diagnostic methods were discovered using Bi-Digital O-Ring Test (BDORT) which uses highly sensitive Electromagnetic Field (EMF) resonance phenomenon between 2 identical molecules with identical weight. Using this, most molecules can be detected non-invasively & rapidly. For this, US Patent was given in 1993. Using 1st method, we can suspect some of the cancers from visible, abnormal deep creases of skin or disappearance of parts of eyebrows in the presence of malignancy at corresponding organ representation area as visible changes. However, some of deep crease may not be malignant. Using BDORT, if it is abnormal (-) value of (-)7 or very high negative value of (-)12, immediately malignancy can be suspected. If visible or invisible abnormal area has BDORT (-)7 or higher, using microscope slide of cancer of specific internal organs we can quickly determine by the presence of strong EMF resonance phenomenon without using biopsy which often spreads cancer at cellular level. We can use following 3 non-invasive, quick confirmation methods: 1) Presence of strong EMF resonance phenomenon with microscope slide of specific cancer tissue. 2) Integrin α5β1 or Oncogene C-fosAb2 is significantly increased. 3) Non-invasive measurement of 8-OH-dG, which is proportional to DNA mutation, which requires for the growth of cancer cells. Early stage cancer is usually 2.5ng but when it is over 10ng or higher, often there is a metastasis. When there is no visible signs of malignancy, we use one-page “Mouth, Hand, & Foot Writing Form” analysis. Its completion by patient after instruction of how to do it, on average it takes about 5-10 minutes for each patient to complete. Once it is completed using cancer-screening kit, which consists of 75 microscope slides of the most common cancers, we can screen any malignancy in less than 1 minute and detection of specific cancer can take anywhere between 5-10 minutes and some patients have more than 3-4 different cancers. Therefore, this 2nd method is most quick, reliable method of making any diagnosis of any cancer or other malignancies without knowing anything about the patient. 3rd method needs strong Physics background on electromagnetic field & the procedure is more time-consuming, experience, & training, since the author discovered this method only 2 years ago, we use it when diagnosis of the patient is questionable and electrocardiogram is already available. In the future, this method may become important cancer-screening test. To prevent cancer, first we screen if there is any indication of early stage of malignancy. When there is early sign of malignancy, Integrin α5β1 and 8-OH-dG are slightly increased but not detectable by standard laboratory tests. For treatment or prevention we have compared effectiveness of optimal doses of Vitamin D3, PPQ, Taurine, & DHEA since we found they are decreased in cancer tissue. However, our recent study revealed 8 unique, beneficial effects of optimal dose of Vitamin D3 including safe, strong anti-cancer effects. We found individually determined optimal dose of Vitamin D3 on average 3 times a day because 1 optimal dose of Vitamin D3 lasts about 8 hours for patient with early stage of cancer. For advanced stage of cancer with metastasis, we use 3~4 times a day with best anti-cancer effects without side effects. When there is no malignancy, optimal dose of Vitamin D3 for average adult is 400I.U. (10 micrograms). Average dose for pre-cancer (which is before standard laboratory tests in detection) is 600I.U.. For patients with early stage of cancer, optimal dose is about 800I.U.. For those with advanced cancer with metastasis, average optimal dose is between 1000-1600I.U.. All these optimal doses should be determined individually & given every 8 hours. According to the Bi-Digital O-Ring Test, optimal dose for each individual is amount which makes any abnormal (-) value of BDORT to (+)12. Optimal dose can change depending on the patient’s condition. Therefore, it should be reevaluated periodically. As exception, some patients with serious liver & kidney disease, Vitamin D3 is ineffective but often optimal doses of one of DHEA, Taurine, or PQQ is highly beneficial. However, if you use overdose of Vitamin D3 such as 2000~5000I.U. or higher, it will promote growth of cancer. One of major problems of current chemotherapy is often individualized optimal dose is rarely used. 

  • Gynecologic Oncology | Breast Cancer | Preventive Oncology

Session Introduction

Arpita Kulshrestha

Rosalind Franklin University of Medicine and Science, USA

Title: Vacuolar ATPase 'a2' subunit is a tumor associated antigen candidate for diagnosis and treatment of ovarian cancer
Speaker
Biography:

Arpita Kulshrestha has completed her PhD in 2012 from National Institute of Pathology, New Delhi, India. Presently, she is pursuing her Post-doctoral Training from Rosalind Franklin University of Medicine and Science. She has published more than 20 papers in peer reviewed journals along with several book chapters.

Abstract:

The identification of novel targets for early diagnosis and development of alternate therapies is vital to patient outcome in ovarian cancer (OVCA). Tumor associated vacuolar-H+-ATPases (V-ATPases) are multi-subunit proton-pumps that acidify the tumor microenvironment, thereby promoting tumor invasion, metastasis and drug-resistance. The subunit ‘a’ of its V0 domain is the major pH-sensing unit. Specifically, its ‘a2’ isoform (V0a2) is critical in metastasis through tumor-acidification and immuno-modulation. Initial evidence suggests that this is an ideal molecule for early diagnosis/treatment of OVCA. We investigated the expression of V0a2 in the clinical tissues from low-grade, high-grade and endometrioid OVCA. Immuno-histochemistry revealed that V0a2 was expressed in both low and high-grade serous-adenocarcinoma with weak staining in normal ovarian tissues. Among different pathological grades, V0a2 expression was significantly higher (p<0.05) in high-grade compared to low-grade serous-adenocarcinoma. The V0a2 expression correlated with Ki67 and CA-125 cancer cell antigen staining, confirming its expression on cancer cells. In these tissues, immuno-fluorescence analysis showed V0a2 localization on the plasma-membrane of cancer cells with no surface expression on normal ovary. V0a2 DNA/RNA-seq studies are ongoing to identify its underlying gene expression and regulation in OVCA. We also examined the presence of V0a2 in infiltrated immune cells in these OVCA tissues. V0a2 was expressed on CD68-positive tumor-associated macrophages (TAMs). In TAMs, V0a2 is known to regulate IL-1β expression leading to angiogenesis. Therefore, we conclude that V0a2 isoform is the plasma-membrane form of V-ATPase-‘a’subunit and is a potential tumor associated antigen candidate to target for diagnosis and treatment of ovarian cancer. 

Zaid Al-Wahab

Oakland University, USA

Title: Gynecologic cancers in pregnancy
Speaker
Biography:

Zaid Al-Wahab has completed his Medical Degree from Al-Nahrain University. He has completed his residency in Obstetrics and Gynecology from Wayne State University/Detroit Medical Center. He then did a Fellowship in Gynecologic Oncology from Karmanos Cancer Institute/Wayne State University. His interest lies in minimally invasive surgery including Robotic Surgery and Sentinel lymph node mapping.

Abstract:

Cancer is an important cause of death in women of childbearing age. Cancer incidence in pregnancy has increased in the last 50 years due to higher rates of cancer and delay in childbearing. Symptoms of cancer can be confounded with pregnancy symptoms. The diagnosis and treatment require a balance of risks and benefits for both maternal and fetal wellbeing. This requires a multidisciplinary approach of different specialties. Management of cancer with surgery, chemotherapy, radiation and hormonal therapy depend on the gestational age, stage of disease and the specific type of treatment

Marta Recio Rodriguez

Complutense University of Madrid, Spain

Title: Sexual dysfunction in the gynecologic oncology patient
Speaker
Biography:

Marta Recio Rodríguez has completed her Medical studies in Universidad Complutense de Madrid (Spain) and continued her foundation for 4 more years with the National Medical Residency System to specialize in Gynecology and Obstetrics. She also has 2 Master degrees, the first one in Sexology and couples therapy, and the second one in Urogynecology and pelvic floor dysfunctions. She is the Coordinator Manager of the Gynaecological and Obstetrics team in Policlinica Nuestra Señora del Rosario in Ibiza and also a Member of the Breast Pathology Unit.

Abstract:

Being diagnosed with gynecological or breast cancer implies confronting the organic and psychological consequences of an illness that affects parts of the body which are full of sexual significance. Together with the actual process of the cancer, the medical and surgical treatments received can cause severe consequences on the patients’ sexuality, including body image and self-esteem. It is the duty of the medical professionals to include a sexual assessment of oncology patients as an integral part of the medical evaluation. The aim of this talk is to deal with the different physical and psychological issues in oncological patients’ sexuality and their correct management. 

Speaker
Biography:

Dr. Gunjan Bhardwaj, Innoplexus AG, CEO and Founder, a consulting-led product and technology firm focused on big data and advanced analytics. Previously he served Boston Consulting Group and Ernst & Young where he led the Global Business Performance think tank.Additionally, Dr. Gunjan Bhardwaj was also an honorary representative of the state of Baden Württemberg to India.He has been publishing in several scientific and business journals such as the Harvard Business Review, MIT Sloan Review, International Journal of Innovation Management and Journal of Service Research. Dr. Gunjan Bhardwaj has studied at Indian Institute of Technology Bombay, Pforzheim Business School,MIT Sloan and European Business School.

Abstract:

Breast cancer is the most common cancer of urban Indian women and the second most common in rural women. Owing to lack of awareness of the disease in India and in absence of breast cancer screening programs, majority of breast cancers are diagnosed at a relatively advanced stage. Government agencies, NGOs and charity organizations have put great emphasis on improved breast cancer awareness among masses for promotion of early detection, providing comprehensive treatment module, providing support for breast cancer management and for screening and rehabilitation. The efforts have resulted in an improved survival and quality of life of Indian breast cancer patients but the improvement is more pronounced in urban population. In rural areas, there is still a lack of good health care and awareness among masses regarding the importance of early breast cancer screening and thus cases of late diagnosis are more prevalent. In addition, there is still an identified lack of breast cancer screening programs in rural areas which further causes late diagnosis. The other common factors that lead to late diagnosis include delays on the part of womenfolk of rural areas to seek advice for a recognized health problem which is mainly due to financial reasons, social/cultural reasons such as general inhibition of women to see the doctor for breast ailments, general scare of people towards cancer like disorders and a general indifference of women towards their health. In rural areas illiteracy is widespread and also people are inhibited and not motivated to come to the hospitals for screening/check-up. Considering various factors of cancer incidence rate, to address the most common barriers such as lower cancer literacy, lesser availability and accessibility of proper medical facilities, three Indian states were shortlisted to initiate the project ECHO by organizing breast cancer awareness and screening programs for rural and semi-urban Indian population. In addition to being a CSR approach, project ECHO also increased the cancer literacy amongst the rural population and emphasized on health education, early diagnosis of breast cancers and more public facilities for breast cancer treatments.

 

Homer S. Black

Baylor College of Medicine, Houston, USA

Title: Pro-Carcinogenic Action of Beta-carotene
Speaker
Biography:

Homer S. Black, Ph.D. was born in Port Arthur, Texas in 1935. He completed high school at Nederland, Texas  in 1952. he entered Texas A & M University and completed a B.Sc. in animal science. He attended Sam Houston State University where he received a M.Ed  and then  attended LSU where he earned a Ph.D. in Plant Biochemistry. He later received a M.S.A. in business/health science management from  the University of Houston.. He joined the Baylor Faculty and Veterans Medical  Center  in 1968..His research has centered  around  UVR-induced skin cancer and antioxidant and dietary lipid modulation of this cancer. He retired in 2003 and  became Professor Emeritus at Baylor College of Medicine. 

Abstract:

Over 600 carotenoids have thus far been identified. About 100  are found in foods consumed by humans. Beta-carotene, as a pre-cursor of vitamin A, can have a profound influence on human health. An epidemiological study in 1981 found that those persons, who consumed foods rich in carotenoids   such as green leafy and yellow vegetables, were at lower risk for cancer.. Beginning in the late 70s, a series of experimental UV-carcinogenesis studies found beta-carotene to be photoprotective. The role of beta-carotene as an anti-cancer agent began to be questioned as a result of intervention studies in which the incidence of non-melanoma skin  cancer was unchanged in patients receiving beta-carotene supplements (1990) and in beta-carotene supplemented smokers who suffered a significant increase in lung cancer occurrence (1996). This was followed by an experimental study (1998) in which beta-carotene supplementation was shown to exacerbate UV-carcinogenic expression. The differences in response to beta-carotene supplementation were ascribed to type of diet, either closed-formula or semi-defined.  A controlled dietary study was conducted in which varying levels of vitamin C and E were fed to animals receiving control and beta-carotene supplemented semi-defined diets. Vitamin C level had no effect on repair of the presumed caroteinoid radical cation. Beta-carotene supplementation resulted in a three-fold increase in tumor multiplicity. However, when the dietary level of vitamin E was reduced, a nearly six-fold increase in tumor multiplicity, compared to control, occurred. The mechanism of beta-carotene exacerbation of UV-carcinogenesis remains speculative, but beta-carotene supplementation should not be recommended as a cancer prevention strategy for the general population

Azita Haddadi

College of Pharmacy and Nutrition, University of Saskatchewan, SK, Canada

Title: Novel Immuno Oncology approches for cancer therapy
Speaker
Biography:

Dr. Azita Haddadi is currently an Associate Professor at the Division of Pharmacy, University of Saskatchewan. She received her Pharm.D. in 1997 and Ph.D. in Pharmaceutical Sciences in 2005. She also completed a 3-year postdoctoral fellowship followed by a Research Associate position at the University of Alberta and a Senior Scientist position at the Quest PharmaTech inc. Dr. Haddadi’s research program focuses on overcoming the ongoing challenges in cancer therapy. The main emphasis of her research is to develop new biomedical and pharmaceutical nanotechnology strategies for cancer chemo-immunotherapy. Her research attracted considerable funding from a number of national organizations in Canada.

Abstract:

In spite of significant advances in recent years towards the development of new therapies, cancer is still a largely unmet medical need and the leading cause of death in industrialised countries. The main challenge in cancer therapy is the patients’ immune suppression leading to tumor relapse and therapeutic failure. Chemotherapy agents are often accompanied by various side effects and poor pharmacokinetics profile. Advancements in nanoparticles as novel drug carriers are rapidly progressing and offer exciting promises. Polymeric nanoparticles for immuno oncology purposes were developed, characterized and applied to improve the efficacy of the immunotherapy and chemotherapy of cancer. The nanoparticles showed significantly superior efficacy compared to conventional treatments. The drawbacks and challenges of the current cancer treatments and different strategies to overcome the issues will be presented and discussed.

Speaker
Biography:

Rajagopal Chattopadhyaya completed his PhD (UCLA,1987) under Richard Dickerson,who as a postdoc solved the 2Å structure of myoglobin under John Kendrew.  Rajagopal did his postdoctoral work at UC Berkeley and Baylor College of Medicine. He has been a faculty member at Bose Institute since 1993, professor since 2006.  His work at Bose Institute is mentioned in the Encycl. Britannica. Book of the Year, 1996 and LexA model in Burton E. Tropp’s Molecular Biology : Genes to Proteins, 3rd edn, a continuation of David Freifelder’s classic undergraduate textbook.  Structural Biologist, biochemist, religious historian & author (as a hobby)

Abstract:

The influence of substoichiometric amounts of seven plant extracts in the Fenton reaction-mediated damage to deoxynucleosides, deoxynucleoside monophosphates, deoxynucleoside triphosphates and supercoiled plasmid DNA were studied to rationalize anticancer properties reported in the extracts Acacia catechu, Emblica officinalis, Spondias dulcisTerminalia belericaTerminalia chebula.  Extracts from these five plants, as well as gallic acid, epicatechin, chebulagic acid and chebulinic acid enhance the extent of damage in Fenton reactions with all monomeric substrates but protect supercoiled plasmid DNA, compared to standard Fenton reactions [1].  However, Dolichos biflorus and Hemidesmus indicus extracts generally do not show this enhancement for the monomeric substrates though they protect plasmid DNA.  Compared to standard Fenton reactions for deoxynucleosides with ethanol, the presence of these five plant extracts render ethanol scavenging less effective as the radical is generated in the vicinity of the target [1].  Since substoichiometric amounts of these extracts and the four compounds produce this effect, a catalytic mechanism involving the presence of a ternary complex of the nucleoside / nucleotide substrate, a plant compound and the hydroxyl radical was proposed [1].  Such a mechanism cannot operate for plasmid DNA as the planar rings in the extract compounds cannot stack with the duplex DNA bases.  These plant extracts, by enhancing Fenton reaction-mediated damage to deoxynucleoside triphosphates, slow down DNA replication in rapidly dividing cancer cells.  In another set of experiments, extracts of Acacia catechuEmblica officinalis, Terminalia belericaTerminalia chebulaSpondias dulcis, completely inhibit human topoisomerase I at 40 μg/ml concentration while Hemidesmus indicus and Dolichos biflorus extracts inhibit partially at the same concentration when included in standard assays [2].  Extracts of the same five plants which inhibit human topoisomerase I strongly are known to possess anticancer activity, while the other two are antioxidant only.  Extracts of Acacia catechuTerminalia chebula and Spondias dulcis show 20 to 80% inhibition of human topoisomerase I at even 9 μg/ml concentration [2].  All seven plant extracts partially inhibit human topoisomerase II at 120 μg/ml concentration in the decatenation assay.  Chebulagic and chebulinic acids purified from Terminalia chebula extract inhibited human topoisomerase I at around 2 μM and 3 μM respectively [2].  The nuclear fragmentation leading to apoptosis observed earlier in cancerous cell lines in the presence of such plant extracts may thus be explained by the inhibition of topoisomerases in addition to modulation of Fenton reaction-mediated damage to DNA constituents.